Mission BioCapital is an early-stage life sciences venture firm based in Cambridge and San Francisco. Its model combines seed capital with access to lab space, shared services, and company-building support through programs such as Platinum. This infrastructure-oriented approach makes it especially useful for founders coming out of research environments.

The firm invests across therapeutics, diagnostics, devices, delivery systems, and research tools, with a portfolio that includes neurodegeneration-related companies such as Alector. While it is not a pure neurotech specialist, its early-stage life sciences orientation makes it relevant to neuroscience startups that require wet lab support, translational guidance, or technical incubation. It is strongest where a company still needs infrastructure as much as investor capital.

Mission BioCapital focuses on the US, especially the Boston/Cambridge and San Francisco ecosystems. For neurotech, it is most relevant to early-stage therapeutic, diagnostic, and device companies that are still building experimental and operational foundations. It is a better fit for infrastructure-heavy scientific startups than for later-stage commercial neuro businesses.

‍